Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Round Table Discussions
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Prostate Cancer and
1 other channel

News · June 15, 2022

ASCO 2022: 177Lu-PSMA-617 Outperforms Cabazitaxel in Metastatic Prostate Cancer Despite Similar Overall Survival Rates

177Lu-PSMA-617 offers greater activity and lower toxicity than cabazitaxel

PracticeUpdate Editorial Team

 

 Save  Recommend
 Share

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading

Recently Updated